Trial Profile
An exploratory, open-label study to evaluate the safety and feasibility of ATIR201, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment), as adjuvant treatment to a T-cell depleted haploidentical hematopoietic stem cell transplantation in patients with beta-thalassemia major
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2019
Price :
$35
*
At a glance
- Drugs T cell replacement therapy TH 9402 (Primary)
- Indications Thalassaemia
- Focus Adverse reactions; First in man
- Sponsors Kiadis Pharma
- 01 Nov 2019 This trial has been discontinued in UK, according to European Clinical Trials Database record.
- 03 Apr 2017 According to a Kiadis Pharma media release, the company has received regulatory approval from the national authority in Germany to initiate this phase I/II study in Germany.
- 16 Mar 2017 According to a Kiadis Pharma media release, trial design will be presented at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).